文献速递免疫规划

ROTAVAC®与Rotarix®在健康婴儿中的免疫原性与安全性随机非劣效4期临床试验

A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants.
PubMed 文献 · Vaccine · 2019-06-06

这项多中心、开放标签、随机4期试验将464名6-8周龄健康婴儿等量随机分配至ROTAVAC®完整3剂方案组或Rotarix®完整2剂方案组,比较血清抗轮状病毒IgA抗体应答。结果显示ROTAVAC®组GMC为20.4(95%CI: 17.6, 23.6),Rotarix®组为24.8(95%CI: 20.3, 30.3),GMC比值为0.82(95%CI: 0.64, 1.05),满足非劣效性标准,且两疫苗安全性特征无实质性差异。

要点

  • ROTAVAC®完整方案对Rotarix®完整方案的GMC比值0.82(95%CI: 0.64, 1.05),达到免疫非劣效。
  • ROTAVAC®组血清阳转率35.3%(95%CI: 29.0, 41.9),Rotarix®组31.0%(95%CI: 25.1, 37.4)。
  • 两疫苗安全性特征无实质性差异,ROTAVAC®现已通过WHO预认证。

核心结论

  • ROTAVAC®完整3剂方案对Rotarix®完整2剂方案在健康婴儿中显示免疫非劣效性,且安全性可接受。

研究设计与样本

  • 多中心、开放标签、随机4期临床试验,464名6-8周龄健康婴儿等量随机分配至ROTAVAC®3剂组(Group I)或Rotarix®2剂组(Group II)。
  • 采用酶联免疫吸附试验(ELISA)检测血清抗轮状病毒免疫球蛋白A(IgA)抗体应答。
  • 主要分析为完整方案接种婴儿的几何平均浓度(GMC)非劣效性评估。
  • 试验注册号CTRI/2015/12/006428。

主要发现

  • Group I的GMC为20.4(95%CI: 17.6, 23.6),Group II为24.8(95%CI: 20.3, 30.3)。
  • GMC比值为0.82(95%CI: 0.64, 1.05),满足非劣效性标准。
  • Group I血清阳转率35.3%(95%CI: 29.0, 41.9),Group II为31.0%(95%CI: 25.1, 37.4)。
  • 两疫苗安全性特征无实质性差异。
  • 站点分析显示一个站点存在特殊疫苗接种前滴度,仅影响ROTAVAC®接种后GMC。

临床怎么用

  • ROTAVAC®完整3剂方案可作为与Rotarix®完整2剂方案免疫非劣效的轮状病毒疫苗选择。
  • ROTAVAC®无需缓冲剂、低剂量体积(0.5 mL)、不干扰其他同时接种疫苗,且符合WHO预认证要求,具备全球广泛使用潜力。

局限性

  • 开放标签设计可能引入偏倚。
  • 一个站点存在特殊疫苗接种前滴度,仅影响ROTAVAC®接种后GMC,可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ROTAVAC® (nHRV), derived naturally from the human 116E rotavirus (RV) neonatal strain, was licensed in India in 2015 based on promising results of a phase 3, safety and efficacy vaccine trial. As a pre-requisite for WHO prequalification, we compared the immunogenicity and safety of ROTAVAC® to those of a WHO-prequalified, Rotarix®. METHODS: We conducted a multicentre, open-labeled, randomized phase 4 clinical trial where 464 infants, 6-8 weeks of age were equally randomized to receive as licensed, the complete regimen of ROTAVAC® (3 doses; Group I) or Rotarix® (2 doses; Group II). Antibody responses (serum anti-RV Immunoglobulin A [IgA]) were measured by enzyme-linked immunosorbent assay (ELISA). The primary analysis was an assessment of non-inferiority of ROTAVAC® to Rotarix® for geometric mean concentration (GMC) for infants who received the complete regimen of either vaccine. RESULTS: The GMC for Group I was 20.4 (95%CI: 17.6, 23.6) and that for Group II was 24.8 (95%CI: 20.3, 30.3), the GMC ratio was 0.82 (95% CI: 0.64, 1.05), thus meeting the non-inferiority criterion. Site-wise analysis of GMC titres revealed that one site had a peculiar pre-vaccination titre affecting only ROTAVAC® post-vaccination GMCs. Seroconversion rates were 35.3% (95%CI: 29.0, 41.9) and 31.0% (95%CI: 25.1, 37.4) for Groups I and Group II, respectively. There was no substantive difference in safety profiles between both vaccines. CONCLUSIONS: The complete regimen of ROTAVAC® demonstrated immunological non-inferiority to the complete regimen of Rotarix® with a clinically acceptable safety profile. Because the demand for RV vaccines is increasing as more countries are expanding their immunization schedules, the lack of need of a buffering agent, low dose volume (0.5 mL), non-interference with other concomitantly administered vaccines, and conformance with WHO-prequalification requirements provide ROTAVAC® the potential for widespread global usage. Post completion of this study, ROTAVAC® is now a WHO-prequalified vaccine. CLINICAL TRIALS REGISTRATION: (CTRI Number: CTRI/2015/12/006428).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ella R, Babji S, Ciarlet M, et al. A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants. Vaccine. 2019. PMID: 31178377. doi:10.1016/j.vaccine.2019.05.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。